AstraZeneca announces that the results of a Phase III trial conducted in Japan with acoramide in adult patients with transthyretin cardiac amyloidosis (ATTR-CM) are consistent with those of the global Phase III study previously conducted by BridgeBio Pharma.

As a reminder, ATTR-CM is a rare, progressive and fatal disease, leading to heart failure and high mortality rates within four years of diagnosis.

' These results are further evidence that stabilizing transthyretins via acoramides can improve survival and reduce disease severity in patients by preventing further degradation of these proteins', commented Yukio Ando, Professor in the Department of Amyloidosis Research at Nagasaki International University (Japan).

These positive results support our ambition to bring acoramide to ATTR-CM sufferers in Japan as soon as possible", added Marc Dunoyer, CEO of Alexion, AstraZeneca's rare disease subsidiary.

The data will be presented at an upcoming medical meeting before being submitted to the Japanese health authority for regulatory review.


Copyright (c) 2024 CercleFinance.com. All rights reserved.